- Target disease: Filarial diseases
- Main partners (since project start): National Museum of Natural History Paris (MNHN), France; Northwick Park Institute for Medical Research, UK; University Hospital of Bonn, Institute of Medical Microbiology, Immunology and Parasitology, Germany.
- Start date:
- Funding (since project start): Department for International Development (DFID), UK; Federal Ministry of Education and Research (BMBF through KfW), Germany; Médecins Sans Frontières/Doctors without Borders; United States Agency for International Development (USAID), USA.
Screening of drug libraries obtained from biotech and pharmaceutical companies, along with active screening of the literature, identified oxfendazole, a veterinary product used for deworming in animals, as a potential candidate macrofilaricidal agent for river blindness.
Oxfendazole is currently under development for the treatment of neurocysticercosis and trichuriasis. Based on highly encouraging pre-clinical efficacy data, DNDi is exploring the possibility of repurposing oxfendazole as a macrofilaricidal treatment for filarial indications.
DNDi is moving ahead with a first-in-human Phase I trial and pharmaceutical development.
Last update: August 2019